Plasmablastic lymphoma (PL/PBL) is a rare type of lymphoma with strong aggressive ability and poor prognosis. Currently,there is a lack of strict diagnostic and therapeutic criteria. In addition to traditional plasma cell markers, SLAMF7 may be a useful adjunct to diagnostic markers for PBL. High-dose chemotherapy combined with bortezomib or lenalidomide may be a promising first-line option for PBL. In second-line therapy, novel therapies such as immune checkpoint inhibitors, CAR-T, and novel targeted agents appear to further improve the survival of patients with PBL. This article mainly reviews the diagnosis, differentiation, first-line treatment of PBL, and treatment of relapsed/refractory PBL, so as to further explore this disease.
题目: 浆母细胞淋巴瘤诊治研究的最新进展.
摘要: 浆母细胞淋巴瘤（plasmablastic lymphoma，PL/PBL）是一种罕见的淋巴瘤类型，具有较强的侵袭能力，预后差，目前缺乏严格的诊断及治疗标准，除了传统的浆细胞标记物作为诊断依据，SLAMF7可能是PBL诊断标志物的有用补充。高强度的化疗方案联合硼替佐米或来那度胺可能有望成为PBL的一线治疗选择。在二线治疗中，免疫检查点抑制剂、CAR-T及新型靶向药物等新的治疗方法似乎能进一步改善PBL患者的生存。本文主要就PBL的诊断及鉴别、一线治疗及复发难治性PBL的治疗等方面进行综合性回顾，以便对该病进行进一步探究.
Keywords: differential diagnosis; plasmablastic lymphoma; treatment.